Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.

Abstract

The aim of this study was to compare outcomes for patients with community-acquired pneumonia (CAP) caused by Legionella spp. following treatment with moxifloxacin or a range of comparator antimicrobial agents. Data were pooled from four sequential I.V./P.O. trials of moxifloxacin in the treatment of CAP. Comparators were ceftriaxone +/- erythromycin, amoxicillin/clavulanate +/- clarithromycin, trovafloxacin, levofloxacin, or ceftriaxone + levofloxacin. Legionella infection was diagnosed by culture, urine antigen testing and/or serology. Clinical success rates for the efficacy-valid (per protocol) populations were recorded at the test-of-cure visit (5-30 days post-therapy). Severity of CAP was determined using the modified American Thoracic Society criteria.Of 1786 efficacy-valid patients, 33 (1.8%) had documented infection with Legionella spp. (moxifloxacin: n=13; comparator: n=20). Of these, 30 cases were identified by serology and/or urine antigen detection and 3 by respiratory culture. The success rate of moxifloxacin vs. comparator therapy was 92.3% vs. 80.0% for the I.V./P.O. trials.Sequential (I.V./P.O.) moxifloxacin demonstrated clinical efficacy that was at least as good as that of comparator treatments for the treatment of CAP due to Legionella.

• Authors: J Garau, A Fritsch, P Arvis, R C Read
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 22 Issue 4 Pg. 264-6 (Aug 2010) ISSN: 1973-9478 [Electronic] England
• PMID: 20685631 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Aza Compounds
• Fluoroquinolones
• Quinolines
• Moxifloxacin

Topics

• Aged
• Anti-Bacterial Agents (therapeutic use)
• Aza Compounds (therapeutic use)
• Community-Acquired Infections (drug therapy)
• Female
• Fluoroquinolones
• Humans
• Legionella
• Legionellosis (drug therapy)
• Male
• Middle Aged
• Moxifloxacin
• Multicenter Studies as Topic
• Pneumonia, Bacterial (drug therapy)
• Quinolines (therapeutic use)
• Randomized Controlled Trials as Topic
• Treatment Outcome